2023 World Conference on Lung Cancer (Posters)-P2.10. Characteristics and Outcomes of Hispanic Patients with RET-Fusion Positive NSCLC Treated in Real-World Practice

P2.10. Characteristics and Outcomes of Hispanic Patients with RET-Fusion Positive NSCLC Treated in Real-World Practice - PDF(Slides)

Back to course

Pdf Summary

This study examined the characteristics and outcomes of Hispanic patients with rearranged during transfection (RET) fusion positive non-small cell lung cancer (NSCLC) treated in real-world practice. The study included 51 patients between January 2016 and April 2023. The majority of patients were female (53%) and had adenocarcinoma (98%). Most patients were never or former smokers (94%). Eleven patients (21.6%) had brain metastases at diagnosis, and 59% had metastases in two sites. The most common fusion partner was KIF5B (72.5%).<br /><br />Genetic analysis revealed that 29.4% of patients had mutations in TP53, 17.6% in CDKN2A/B, and 7.8% in SETD2. The median tumor mutational burden (TMB) was 2 Mt/Mb, with only 10% of patients having a TMB value of 5 Mt/Mb or higher. PD-L1 expression was varied, with 31.4% of patients having a PD-L1 expression of 0%, 41.2% between 1-49%, and 13.7% at 50%.<br /><br />Treatment regimens included CTICI (60.8% in the first line), CT (19.6%), some MKI (9.8%), and RETsi (9.8%). The overall response rate (ORR) to the first-line treatment was 43.5%, and the median progression-free survival (PFS) was 7.7 months. Median overall survival (OS) was 30.6 months. In the second line, targeted therapies (MKIs or RETsi) showed a longer PFS (17.2 months) compared to CT or CTICI (6.2 months).<br /><br />In conclusion, Hispanic patients with RET fusion NSCLC exhibited similar biological behavior. The first-line treatment outcomes were consistent with the existing literature. However, the number of patients receiving RETsi treatment in both the first and second lines was limited, despite showing advantages in OS and PFS in the second line. The study suggests the need for a regional effort to promote the rapid introduction of RETsi treatment in Latin America.

Asset Subtitle

Oscar Arrieta

Meta Tag

Speaker Oscar Arrieta

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

Hispanic patients

RET fusion positive NSCLC

adenocarcinoma

brain metastases

KIF5B fusion partner

TP53 mutations

PD-L1 expression

CTICI treatment

MKI targeted therapy

Latin America